Background: Breast cancer is the most common cancer diagnosis among women worldwide. It accounts for 25% of all women's cancers. This cancer is invasive with a high mortality rate. Evaluation of hematological factors is one of the reliable paraclinical methods to diagnose diseases. Hematological parameters can predict severity, mortality, and follow-up treatment in patients with breast cancer. The aim of this study was to evaluate hematological parameters as useful markers to distinguish between patients with breast cancer and healthy individuals.
Methods: This study was conducted on 160 women with breast cancer as case groups and 160 healthy women as controls. Hematological parameters were analyzed using the Sysmex KX-21N™ automated hematology analyzer system.
Results: The difference between the breast cancer patients and the control group was significant in Hb, HCT, MCV, RDW parameters, and MPV/PLT ratio (p < 0.05) (effect size > 0.8). Also, there was a moderate difference between the two groups in MPV and MCH parameters (p < 0.05) (0.5 < effect size < 0.8). Meanwhile, two groups had a minimal difference in NLR, PLR, and MCHC parameters and WBC and RBC count (p < 0.05) (0.2 < effect size < 0.5).
Conclusions: The routine blood test is the most accessible and essential examination tool for disease diagnosis. Our results showed that hematological parameters, like MCV, RDW, MPV, MPV/PLT count, NLR, and PLR, can differentiate breast cancer patients from healthy individuals.